BMEA Biomea Fusion Inc

$BMEA Back in June when Cohort 5 was announced; I suggested it was at the request of BP because it fits exactly with what BP Board would demand. BMF-650 is likely to print a clean PK, 1 step titration & 6% weight loss in 28 days. Scientific sense. The Aug 24, ICO announcement fits precisely with a BP 30 day ROFR option, as did the massive volume & price increase that week. The Sept 22 raise, followed by the BMF-500 clinical trial closure 4 hours later & then 14 hrs later the raise being killed; fits with a balance sheet clean up. The fact BMF-650 was delayed is the icing. It's a 12 pt, 1 location, Medpace Phase 1 trial. The data wwas definitely locked by Aug 31. In order to clean a balance sheet for M&A, BMF-500 has to be sent out; perhaps to BMEA-ONCO. A look at upcoming metabolic Symposiums in Oct show BMEA are not scheduled to attend any. Sanofi M&A could occur in Oct. Licensing possible but less likely. SEC Regs would permit BP access to BMF-650 data under this scenario.

$BMEA Between yesterday’s after-hours session and today’s trading, my average is now around $2.xx. I honestly can’t believe it, especially considering where I started—I was a multi-year bagholder with an average around $37. At this point, it feels like an all-or-nothing position. I can’t even tell you how many shares I hold; the number is not exactly respectable. A share price around 2.xx could finally bring me back into positive territory. After so many years of sleepless nights I still can’t believe this might actually happen.

$BMEA Your childish attitude is worse than 's, whom you criticized so much. At least creisi is consistent in his attitude. He's been bullish from the beginning to the end, whatever that end may be. I'm very disappointed by your behavior. It's 100% your right to divest from Biomea and be disappointed — no issue there. But coming back here to say you never believed in it, and now loudly announcing you've switched sides by shorting and buying puts, that's simply bashing. Whatever your goal may be in doing this, believe me, it won't impact the stock. Most people here hold long-term positions that started a long time ago. They don't care about some random person on a forum saying "hey guys, I'm out." And to be honest, most people here hold so few shares (whatever they claim) that it wouldn't make any difference anyway. What I do see is that the major institutional shareholders are still here and haven't changed their positions. That's a strong sign of trust.

$BMEA Big catalyst confirmed for this Saturday, Oct 10 (10:10 AM ET) at the Breakthrough T1D Congress. Dr. Steve Morris (CDO) will deliver an oral podium presentation on Phase 2 COVALENT-112 data: "Icovamenib Shows Evidence of Enhanced Endogenous Insulin Secretion in T1D". This is important: 1. Biological Breakthrough: BMF-219 targets true disease modification. An oral menin inhibitor showing restored C-peptide and preserved endogenous insulin months post-treatment is fundamentally different from daily insulin substitution. 2.KOL & Institutional Spotlight: Selection by Breakthrough T1D (formerly JDRF) puts these findings right in front of the global endocrinology leaders and potential pharma partners ($LLY , $NVO). 3. Asymmetric Risk/Reward: With EV compressed near net cash following previous regulatory overhang, any clinical validation of durability could trigger an aggressive re-rating. A potentially paradigm-shifting oral approach in a multi-billion TAM. Eyes on the data Saturday. 📈

$BMEA Really strange day today. We will see how this all unfolds. I have not written off BMEA. The guidance for Oct data was likely because the offering needed to be closed. This means data could come sooner. I will say this: I did write Mick Hitchcock and Ramses Erdtmann. I know some might be like So what... Well, I have a history of getting in contact with CEOs of Biotechs. So we will see. I also have Mick's cell from a tool I own. I sent them over some very compelling data on what could unfold if they make some smart moves from here. We will see how they react, but again, I haven't written this off yet.

$BMEA I still think this has a higher chances of working out then not but I might eat my words on this. Average translation % gets us to 5.5% weight lose cohorts 1 to 4 and 6.2% cohort 5. That would send this regardless of the mess they have made.

$BMEA “we recommend investors revisit this story sooner rather than later” 9/30/26 - $7 price target does not include potential upside from BMF-650

$BMEA When you zoom out and realize the company have 5 distinct shots (even though there is drug crossover) to become a billion dollar + company then it makes you feel better. As humans we are naturally impatient but this isn't a day trade play. That's just pure gambling and speculation and you may as well play plinko. If all five shots fail then yeah that sucks but I would say that odds of that are very low based on results so far. I ran some (very amateuristic and AI supported models) and the IP assets even in a distressed fire sale will yield probably a buck a share even taking into account dilution and warrant exercises. Essentially there's another 30% downside from here, but potentially 3000% upside. I like those odds and it's worth the gamble in my humble opinion. I know there are people who bought in above 30 and that truly truly sucks and I'm really sorry but anyone who's average is below two dollars has a ticket with remarkable risk / reward characteristics. Good luck!

$BMEA The unfortunate episode of the public offering pulled at the end of September will be quickly forgotten if BMF-650 and/or BMF-219 report strong efficacy data. Maybe they even deliberately caused this mess to shake out the retail shareholders in favor of long-term institutions. And don't come telling me 'no, that's not allowed,' etc. Unfortunately, it's common practice and impossible to prove. In any case, the stock is a heavily coiled spring. If the data is good, the move is going to be violent. Given the assets in the portfolio/pipeline, this is a double-digit price minimum. And unlike TheSuper, I'm convinced icovamenib is going to be ultra-positive. We've already seen it in the published data, and mechanistically in both T1D and T2D.

$BMEA companies with positive trial results and financial health hire new employees. Bad data / bad financial health = layoffs. Strong buy!

$BMEA started thinking about this more. This failed offering was even more impactful long term then I first realized. With data delay and price drop they also might have fucked themselves with the warrants at 2.5 for Dec. They now risk the chance of funding from that as well. So if they dont pull off good data and a price $2.5+, really 3.00 or more, they are going to not have the warrant funding either. Which means next raise expect like 50 to 100m shares. Massive diluation. So either they are extraordinary stupid or there is a master plan. I have to lean hard on the "they are just stupid as fuck side."

$BMEA it’s interesting that in the last 3 months most of the search results for Biomea Fusion came from Denmark. Maybe some interest from Novo Nordisk? 🤔

$BMEA Just to make this really clear; as a microcap director in biotech facing cash constraints you can not vote to cancel or yank an equity raise unless a guaranteed alternative option to raise cash has just materialized. It is a serious legal Breach of Fiduciary Duty to cancel an equity raise for a company facing cash constraints. You don't just pay professionally, all your personal assets would be taken as well. Here are 2 indisputable key points 1. The order book and price would have been built & agreed to last week. Not Tuesday night. This is how it's done. Anyone saying otherwise is an idiot. 2. BMEA cancelled the raise, not KP. This immediately raises Director Fiduciary Duty issues. The likely reason a Board is empowered to cancel a required raise is because they have a non-dilutive funding event, licensing deal, or buyout term sheet sitting on the table that is contingent on a data package that was just received. It is very likely, Astellas is the buyer of BMF-500.

$BMEA the other thing to note is companies, brokers ect who own the stock know when options expire worthless they get paid on the calls they wrote. So after investing for 35 years my conclusion is it’s ok for me to write options on stock I own. It’s not ok to buy options on a stock I don’t own. We are in the month of October to LFG.

$BMEA Ole Creisi may be on to something here as a Sanofi buyout was one of the reasons I initially invested in BMEA. I have been hoping that Sanofi would buyout / partner with GPCR, but if they don't want to spend big money for GPCR, their next best option for an oral small molecule would be BMEA (assuming positive Ph1 data). Sanofi would mainly want BMF-650, but about 5% of their revenue comes from Diabetes and that has been dropping recently, so they may also want Icova.

$BMEA Hmmm … $SMMT cancelled their public offering back in early June. About three months later.. this news.

$BMEA this is mainly for newer people. BMF-650 >>>>>> The catalyst to get funding we need (at fair prices). Icovamenib >>>>>> The thing that could change our lives.

$BMEA well, KURA upstaging us at EASD and $MLTX Merck upstaging us at EADV and all updates still pending isn't the way I saw the quarter closing.

$BMEA before I bounce from work, and the weekend actually starts for me. I believe in the science the company has and the leadership. My opinion is this is some sort of an mos communication with the timing on the PR thus it’s retracted. Also more important is this is a great room and should be inclusive of everyone. Remember I think the majority in here is long or following the stock. Talking about creisi he has stock what ever the number and I’m annoyed I’m now blocked because the atmosphere in the room or the temperature changed. Be chill and let’s let it play out and we all get paid in the end. More unity is my message civil discourse. Enjoy the time with the Fam it’s finally fall.

$BMEA Let's make this really clear: As corporate directors management owes a strict duty of care and duty of loyalty to shareholders. Executing a highly dilutive, discounted share offering while sitting on a finalized data package that secures non-dilutive cash would be a textbook Breach of Fiduciary Duty. Period. SEC Regulation of Fair Disclosure 100% stops the equity raise and also stops BMEA management from talking, right now. This is why management has gone completely silent. They cannot legally defend themselves or hint at an ongoing licensing negotiation until a definite contract is signed and filed. That is the law. As a director I fuckin' hated it but had no choice but take the short bashing. It's how it works.